Changeflow GovPing Pharma & Drug Safety Pyrimidine Tricyclic Derivative and Pharmaceuti...
Routine Rule Added Final

Pyrimidine Tricyclic Derivative and Pharmaceutical Application (EP4417613A1)

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

EPO granted patent EP4417613A1 to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. The patent covers pyrimidine tricyclic derivatives and their pharmaceutical applications. The patent is designated in multiple contracting states including DE, FR, GB, IT, ES, NL, SE, PL, and other EU member states.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

EPO granted patent EP4417613A1 for pyrimidine tricyclic derivatives and pharmaceutical applications. The patent designates multiple contracting states across the EU. Inventors include LUO Yunfu, ZHANG Guoli, LI Shaolong, GE Weizhi, and CHEN Shuhui.

Pharmaceutical companies developing or manufacturing compounds in this chemical space should conduct freedom-to-operate analyses to assess potential patent conflicts. The patent covers heterocyclic compounds (C07D 519/00, C07D 487/04, C07D 487/06) classified under A61K 31/519 with therapeutic applications in cardiovascular disease (A61P 9/00).

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PYRIMIDINE TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF

Publication EP4417613A1 Kind: A1 Apr 08, 2026

Applicants

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Inventors

LUO, Yunfu, ZHANG, Guoli, LI, Shaolong, GE, Weizhi, CHEN, Shuhui

IPC Classifications

C07D 519/00 20060101AFI20250602BHEP C07D 487/04 20060101ALI20250602BHEP C07D 487/06 20060101ALI20250602BHEP C07D 498/14 20060101ALI20250602BHEP C07D 498/16 20060101ALI20250602BHEP A61K 31/519 20060101ALI20250602BHEP A61P 9/00 20060101ALI20250602BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4417613A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting IP registration
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!